Xvivo Perfusion Q3: Below expectations

Research Note

2017-10-27

09:29

Sales in Q3 came in lower than our forecast, affected by a negative currency effect. Operating costs were lower than expected, resulting in an EBIT that was in line with expectations. The company provided an update on the ongoing clinical trials, which are progressing according to plan. Our fair value remains unchanged at SEK 105 per share.

AN

Arvid Necander

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.